Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Mayne Pharma Group ( (AU:MYX) ).
Goldman Sachs Group, Inc. has increased its voting power in Mayne Pharma Group Limited from 7.54% to 8.55% by acquiring additional fully paid ordinary shares. This change in substantial holding indicates a growing interest and investment by Goldman Sachs in Mayne Pharma, potentially impacting the company’s market positioning and signaling confidence in its future prospects.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceuticals. The company is known for its diverse range of oral and topical products, serving markets in Australia and internationally.
Average Trading Volume: 910,549
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$400.5M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue